Company Name | Gilead Sciences Hong Kong Limited, Taiwan Branch |
---|---|
Protocol Number | GS-TW-380-5727 |
Title of Study | Multi-country, non-interventional, cohort study of the effectiveness, safety, adherence, and health-related quality of life in HIV-1 infected adult patients receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Asia. |
Primary Objective | To evaluate HIV-1 RNA suppression, defined as HIV 1 RNA <50 copies/mL, at 12 months after initiating or switching to B/F/TAF |
Number of Sites | 14 |
Period of Study | From:2021 Q1 to:End of data collection: Q4 2023; Final Clinical Study Report: Q2 2024 |
Number of Patients | 350人 |
IRB Approval Date | Changhua Christian Hospital:2020/12/09 Kaohsiung Medical Chung Ho Memorial University Hospital:2020/10/27 National Taiwan University Hospital:2020/11/13 Far Eastern Memorial Hospital:2021/04/20 Taoyuan General Hospital: 2021/04/19 Kaohsiung Veterans General Hospital:2020/11/18 |
Publication Plan / Date | Taiwan AIDS Society: 2023; Asia-Pacific AIDS & Co-infection Conference, APACC: 2023; Taiwan AIDS Society: 2024; Asia-Pacific AIDS & Co-infection Conference, APACC: 2024 |